Disrupting Drug Costs: The Role of Cost‐Plus Pricing in Reducing Medicare Spending on Hypertension Treatments

Objective To assess potential Medicare cost savings if Mark Cuban Cost Plus Drug Company (MCCPDC) pricing were applied to antihypertensive medications. Study Setting and Design We conducted a cross‐sectional analysis comparing Medicare Part D spending with MCCPDC pricing for selected antihypertensive drugs. Data Sources and Analytic Sample Eighty‐seven antihypertensive medications were compared between Medicare Part D and MCCPDC. Volume‐adjusted expenditure estimates were calculated under three scenarios: (1) applying MCCPDC prices to all medications, (2) applying MCCPDC prices only to drugs priced lower than Medicare, and (3) applying MCCPDC prices to guideline‐recommended first‐line therapies. Principal Findings In 2022, Medicare spent $4.9 billion on the included medications. Of these, 39 of the 30‐count and 58 of the 90‐count medications showed cost savings under MCCPDC pricing. Estimated savings totaled $670.1 million (30‐count) and $1.4 billion (90‐count). Among 47 first‐line agents, MCCPDC pricing produced estimated savings of $222.6 million (30‐count) and $584.1 million (90‐count). The average 90‐count price reduction was 23.2% overall and 21.1% among first‐line therapies, with several agents showing substantial price advantages. Conclusion Adopting MCCPDC pricing could reduce Medicare costs for antihypertensive drugs, especially through 90‐count supplies and first‐line therapies. Targeted implementation—focusing on medications with clear cost and clinical advantages—may yield meaningful savings. These results support broader policy efforts to incorporate transparent, value‐based drug pricing models into Medicare.